These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3281808)

  • 41. Effect of aspirin on experimental diabetic nephropathy.
    Moel DI; Safirstein RL; McEvoy RC; Hsueh W
    J Lab Clin Med; 1987 Sep; 110(3):300-7. PubMed ID: 3475395
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diabetic glomerulopathy in young IDDM patients. Preventive and diagnostic aspects.
    Rudberg S; Osterby R
    Horm Res; 1998; 50 Suppl 1():17-22. PubMed ID: 9676992
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes.
    Cherney DZ; Sochett EB; Miller JA
    Kidney Int; 2005 Oct; 68(4):1722-8. PubMed ID: 16164648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antagonist for atrial natriuretic peptide receptors ameliorates glomerular hyperfiltration in diabetic rats.
    Kikkawa R; Haneda M; Sakamoto K; Koya D; Shikano T; Nakanishi S; Matsuda Y; Shigeta Y
    Biochem Biophys Res Commun; 1993 Jun; 193(2):700-5. PubMed ID: 8390251
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Are glomerular hyperfiltration and hyperperfusion involved in the development and progression of nephropathies?].
    Kokot F; Kuska J
    Z Urol Nephrol; 1988 Jun; 81(6):359-66. PubMed ID: 3063012
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rapidly progressive glomerulonephritis superimposed on diabetic glomerulosclerosis. Recognition and treatment.
    Carstens SA; Hebert LA; Garancis JC; Piering WF; Lemann J
    JAMA; 1982 Mar; 247(10):1453-7. PubMed ID: 7057537
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Angiotensin-converting enzyme inhibitors in the prevention of experimental diabetic glomerulopathy.
    Myers BD; Meyer TW
    Am J Kidney Dis; 1989 Jan; 13(1):20-4. PubMed ID: 2643307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of hypertension on glomerular structures and capillary permeability in passive Heymann glomerulonephritis.
    Iversen BM; Ofstad J
    Microvasc Res; 1987 Sep; 34(2):137-51. PubMed ID: 3670111
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass.
    Anderson S
    Hypertension; 1991 Mar; 17(3):288-95. PubMed ID: 1999359
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vasoregulatory hormones and the hyperfiltration of diabetes.
    Bank N; Lahorra MA; Aynedjian HS; Schlondorff D
    Am J Physiol; 1988 Feb; 254(2 Pt 2):F202-9. PubMed ID: 2449821
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diabetic nephropathy. A perspective.
    Mauer SM; Steffes MW; Goetz FC; Sutherland DE; Brown DM
    Diabetes; 1983 May; 32 Suppl 2():52-5. PubMed ID: 6400668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.
    Tonneijck L; Muskiet MH; Smits MM; van Bommel EJ; Heerspink HJ; van Raalte DH; Joles JA
    J Am Soc Nephrol; 2017 Apr; 28(4):1023-1039. PubMed ID: 28143897
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes.
    Allen TJ; Waldron MJ; Casley D; Jerums G; Cooper ME
    Diabetes; 1997 Jan; 46(1):19-24. PubMed ID: 8971091
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of angiotensin-converting enzyme inhibition in diabetic rats with reduced renal function.
    Geiger H; Bahner U; Vaaben W; Dammrich J; Heidland A; Luft FC
    J Lab Clin Med; 1992 Dec; 120(6):861-8. PubMed ID: 1453108
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes.
    Vora JP; Oyama TT; Thompson MM; Anderson S
    Diabetes; 1997 Jan; 46(1):107-12. PubMed ID: 8971089
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vivo visualization of glomerular microcirculation and hyperfiltration in streptozotocin-induced diabetic rats.
    Satoh M; Kobayashi S; Kuwabara A; Tomita N; Sasaki T; Kashihara N
    Microcirculation; 2010 Feb; 17(2):103-12. PubMed ID: 20163537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension.
    Dworkin LD; Hostetter TH; Rennke HG; Brenner BM
    J Clin Invest; 1984 May; 73(5):1448-61. PubMed ID: 6715546
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat.
    Cooper ME; Allen TJ; Macmillan PA; Clarke BE; Jerums G; Doyle AE
    Diabetologia; 1989 May; 32(5):326-8. PubMed ID: 2546846
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: the Renin-Angiotensin System Study.
    Klein R; Zinman B; Gardiner R; Suissa S; Donnelly SM; Sinaiko AR; Kramer MS; Goodyer P; Moss SE; Strand T; Mauer M;
    Diabetes; 2005 Feb; 54(2):527-33. PubMed ID: 15677511
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of p38 mitogen-activated protein kinase inhibition on blood pressure, renal hemodynamics, and renal vascular reactivity in normal and diabetic rats.
    Komers R; Schutzer W; Xue H; Oyama TT; Lindsley JN; Anderson S
    Transl Res; 2007 Dec; 150(6):343-9. PubMed ID: 18022596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.